

Charity Registration No. 1158789

HISTIOCYTOSIS UK

KNOWN AS

HISTIO UK

ANNUAL REPORT AND UNAUDITED FINANCIAL STATEMENTS

FOR THE YEAR ENDED 31 MARCH 2025

**HISTIOCYTOSIS UK
HISTIO UK
LEGAL AND ADMINISTRATIVE INFORMATION**

Trustees	Mr A Kontoyannis, Chair Prof. P Beverley Dr V Nanduri Mr P Bienenstock Prof. M Collin Dr R Tattersall
Other officers	Lynn Jackson, Executive Director
Charity number	1158789
Principal address	PO Box 159 Liskeard Cornwall PL14 9DQ
Independent examiner	TC Group 33 Boston Road South Holbeach Spalding Lincolnshire PE12 7LR
Bankers	CAF Bank Limited 25 Kings Hill Avenue Kings Hill West Malling Kent ME19 4JQ

**HISTIOCYTOSIS UK
HISTIO UK
CONTENTS**

	Page
Trustees' report	1 - 5
Statement of trustees' responsibilities	6
Independent examiner's report	7
Statement of financial activities	8
Balance sheet	9
Notes to the financial statements	10 - 17

**HISTIOCYTOSIS UK
HISTIO UK
TRUSTEES' REPORT**

FOR THE YEAR ENDED 31 MARCH 2025

The trustees present their annual report and financial statements for the year ended 31 March 2025.

Resignations

Prof. C Booth on 31st August 2024

Objectives and activities

Public benefit

- The object of the CIO is the relief of sickness and preservation of good health among patients affected by histiocytic diseases their families and carers, in particular but not exclusively by:
- (i) the promotion and furtherance of scientific research into the physiology and pathology of histiocytes and the aetiology of histiocytotic diseases, the useful results of which will be disseminated for the public benefit;
- (ii) the development of more accurate means of diagnosis, improved protocols for management of patients and ultimately measures for prevention of histiocytic diseases;
- (iii) the provision and dissemination of information, education and knowledge in support of patients and families affected by the disease to include the medical professions and general public;
- (iv) collaboration with interested individuals and organisations.

The Trustees confirm that they have referred to the guidance contained in the Charity Commission's general guidance on public benefit when reviewing the Charity's aims and objectives and in planning future activities and setting the grant making policy for the year.

The Charity carries out these objectives by focusing on these areas through which we achieve our strategic priorities of maintaining a stable programme and the continued funding of vital research. The benefits of the Charity's work are the development of future research, the dissemination of research findings, the development of new therapies and the funding of on-going research with the goal being able to inform sufferers, their carers and families.

The trustees confirm that they have complied with the requirements of section 17 of the Charities Act 2011 to have due regard to the public benefit guidance published by the Charity Commission for England and Wales.

Financial Report

Investment policy and objectives

The Charity's policy at present is to invest in low-risk and reasonably liquid assets, so that funds are available to meet any unforeseen needs that may arise, for example, as a consequence of meeting activities.

As far as possible, the Charity seeks to follow an ethical investment strategy that precludes investing in any company whose activities may have an adverse impact on the underlying beneficiaries of the charity. While striving for the highest ethical standards, the Charity will adhere to the Charity Commission's rule that we maximise the income of the charity without exposure to undue risk.

**HISTIOCYTOSIS UK
HISTIO UK
TRUSTEES' REPORT (CONTINUED)
FOR THE YEAR ENDED 31 MARCH 2025**

Financial review

The Chairman regularly reviews the reserves of the charity to ensure that sufficient liquid funds are available to the Charity to meet its ongoing obligations. The reserves throughout the accounting period have been adequate to fulfil this objective.

Income & Expenditure Summary

The 2024-2025 income remained steady against the previous financial year. Charities are in general suffering from the continued downturn in the cost of living, raising ongoing concerns about the "cost of giving" in this economic climate.

We thank all of our generous donors, the individuals, community groups, schools, corporate supporters, Charities and Foundations that continued their support and reflects the excellent participation, drive and generosity of our community fundraisers, supporters, families and committed individuals that have been able to assist us maintain the Charity.

Grant Awards

Histio UK placed a call for Research Papers, after substantial review by the Scientific Review Board and confirmation of the Board of Trustees an award offer was made to: Dr Claire Shannon-Lowe and her team for a project to Understand the role of Myeloid derived suppressor cells in the pathogenesis of Epstein Barr virus-associated HLH.

Grants Received

Nil in the financial year

Chairperson's Statement

Financial

Reflecting on this past year of operation, we acknowledge the support received in terms of funds and the contributions of our volunteers and Histio Champions. We also recognise that the current economic climate affects not only us but also our Histio Community and others, making it a challenging period for everyone.

The Charity acknowledges the likelihood of reduced income for the future and continues to adjust practices and budgets accordingly.

We are very pleased to have continued and further developed our various Histiocytic information guides and social media platforms allowing us to engage further with our Patients, Parents and Supporters.

In collaboration with our partners, we will maintain our commitment to providing histiocytic professionals, patients, and families with the most current information regarding these serious and devastating disorders as it becomes available.

Thank you all.

**HISTIOCYTOSIS UK
HISTIO UK
TRUSTEES' REPORT (CONTINUED)
FOR THE YEAR ENDED 31 MARCH 2025**

Partnerships

Hi-HASC- Haemophagocytic Lymphohistiocytosis (HLH) Across Speciality Collaboration
Histio UK provides website administrative support to this amazing group.

UK Histio Registry –

Histio UK provides website administration to this established registry program.

PPPIE Panel – Patient, Parent, Public Involvement & Engagement Panel

Histiocytosis UK is committed to meaningful patient and public involvement and public engagement for and on behalf of not only its own Grant Fund Awards but to appraise those of other Researchers and or Organisations in the field of research with priority to those of Histiocytic diseases.

Our vision with regards to patient, parent and public involvement and engagement is-

“to establish a culture within Histiocytosis UK where our community has the skills and resources to optimise and deliver patient and public involvement and engagement and it is integrated in to our ways of working and throughout the research we fund and appraise”

Histiocytosis UK has, in consultation with researchers, public contributors and involvement professionals, identified 6 aims that will guide Histiocytosis UK and its engagement programme to work towards it's vision that No one should die of Histiocytosis:

- Ensure our research community incorporates patient and public involvement and engagement throughout research.
- Incorporate relevant involvement throughout our funding processes.
- Lead by example in our involvement and engagement practice.
- Strengthen involvement and engagement practice of Histio UK's Patient, Parent & Public Involvement Engagement Panel.
- Inspire and encourage inclusive, innovative, diverse and creative patient, parent and public involvement and engagement.
- Improve the knowledge sharing of patient, parent and public involvement and engagement.

The Histiocyte Society

The HS is the organisation representing clinical and research professionals in the field of Histiocytic disorders.

The Nikolas Symposium on Histiocytosis

The Nikolas Symposium is the leading scientific think-tank focused on a group of rare diseases called Histiocytic disorders. This international research symposium is dedicated to fostering innovative research.

Awareness

Histiocytosis UK 2024 /2025 – Bite Size-Lets Talk & Share your Voice

This year we expanded our Share your Voice program to include Bite-Size enabling Histio Professionals and Patients to share their experience and journeys.

HISTIOCYTOSIS UK
HISTIO UK
TRUSTEES' REPORT (CONTINUED)
FOR THE YEAR ENDED 31 MARCH 2025

Plans for the future

Histio UK, remains at the forefront in challenging these devastating disorders, we will continue to build on the transfer of information and knowledge available nationally and internationally through our committee structure to parents, patients and medical professionals.

Structure, Governance and Management

Histiocytosis UK is a registered charity, number 1158789, and is constituted as a charitable incorporated organisation in England and Wales.

The Charity actively fundraises and seeks to continue the charitable work desired by the donor through the careful stewardship of its existing resources.

At the annual Trustees' meetings, the Trustees agree the broad strategy and areas of activity for the Charity, including consideration of grant making, investment, reserves and risk management policies and performance.

The day-to-day administration of grants and the processing and handling of applications prior to consideration by the Charity is delegated to the Executive Director.

The Charity's Independent Scientific Review Board consider all applications against agreed criteria prior to making recommendation to the Charity on funding grants. The SRB review all applications received in response to calls for proposals.

The Chair of the SRB for 2024-2025 - Professor Peter Beverley MBBS, DSc, FMedSci.
Vice-Chair - Professor Matthew Collin. BM, BCh, DPhil, MRCP, FRCPath.

The Trustees regularly review the skills and composition of their body and conduct succession planning. They recruit new Trustees based on experience, empathy, and knowledge of the charity. This year, the Trustee Board introduced and collaborated with an elected Advisory Panel.

As we move into our new financial year Trustees will retire at the end of their term of office with the Charity. As always, we will take this opportunity to review our Governance structure and assess the benefits of utilising any opportunities that may be derived from advisory boards allowing us to more fully support the Executive Director in forthcoming projects and initiatives and at the same time focus on our strengths.

Fundraising Regulation

The Charity is registered with the Fundraising Regulator and is in full compliance with its requirements. The Charity adheres to the key principles and behaviours in that the work of its fundraising will be Legal, Open, Honest and Respectful.

Risk management

The Trustees have considered the major risks to which the charity is exposed and have reviewed those risks and established systems and procedures to manage those risks.

The Trustees consider variability of investment returns.

HISTIOCYTOSIS UK
HISTIO UK
TRUSTEES' REPORT (CONTINUED)


FOR THE YEAR ENDED 31 MARCH 2025

Our thanks

The Charity wishes to express its gratitude to all our volunteers for their fundraising activities, technical skills, and participation in virtual and physical events that have taken place throughout the country in this difficult year.

Our thanks to our Corporate donors including those with match funding programmes which encourage our supporters with their own fundraising activities.

The trustees' report was approved by the Board of Trustees.



Mr A Kontoyannis, Chair
Trustee

Dated: 17-06-2025

HISTIOCYTOSIS UK
HISTIO UK
STATEMENT OF TRUSTEES' RESPONSIBILITIES
FOR THE YEAR ENDED 31 MARCH 2025

The trustees are responsible for preparing the Trustees' Report and the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).

The law applicable to charities in England and Wales requires the trustees to prepare financial statements for each financial year which give a true and fair view of the state of affairs of the charity and of the incoming resources and application of resources of the charity for that year.

In preparing these financial statements, the trustees are required to:

- select suitable accounting policies and then apply them consistently;
- observe the methods and principles in the Charities SORP;
- make judgements and estimates that are reasonable and prudent;
- state whether applicable accounting standards have been followed, subject to any material departures disclosed and explained in the financial statements; and
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the charity will continue in operation.

The trustees are responsible for keeping sufficient accounting records that disclose with reasonable accuracy at any time the financial position of the charity and enable them to ensure that the financial statements comply with the Charities Act 2011, the Charity (Accounts and Reports) Regulations 2008 and the provisions of the trust deed. They are also responsible for safeguarding the assets of the charity and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

HISTIOCYTOSIS UK
HISTIO UK
INDEPENDENT EXAMINER'S REPORT
TO THE TRUSTEES OF HISTIOCYTOSIS UK

I report to the trustees on my examination of the financial statements of Histiocytosis UK (the charity) for the year ended 31 March 2025.

Responsibilities and basis of report

As the trustees of the charity you are responsible for the preparation of the financial statements in accordance with the requirements of the Charities Act 2011 (the 2011 Act).

I report in respect of my examination of the charity's financial statements carried out under section 145 of the 2011 Act. In carrying out my examination I have followed all the applicable Directions given by the Charity Commission under section 145(5)(b) of the 2011 Act.

Independent examiner's statement

Your attention is drawn to the fact that the charity has prepared financial statements in accordance with Accounting and Reporting by Charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) in preference to the Accounting and Reporting by Charities: Statement of Recommended Practice issued on 1 April 2005 which is referred to in the extant regulations but has now been withdrawn.

I understand that this has been done in order for financial statements to provide a true and fair view in accordance with Generally Accepted Accounting Practice effective for reporting periods beginning on or after 1 January 2015.

I have completed my examination. I confirm that no matters have come to my attention in connection with the examination giving me cause to believe that in any material respect:

- 1 accounting records were not kept in respect of the charity as required by section 130 of the 2011 Act; or
- 2 the financial statements do not accord with those records; or
- 3 the financial statements do not comply with the applicable requirements concerning the form and content of accounts set out in the Charities (Accounts and Reports) Regulations 2008 other than any requirement that the accounts give a true and fair view which is not a matter considered as part of an independent examination.

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the financial statements to be reached.



Christopher McKenna ACA

TC Group
33 Boston Road South
Holbeach
Spalding
Lincolnshire
PE12 7LR

Dated: 23/7/25

HISTIOCYTOSIS UK
HISTIO UK
STATEMENT OF FINANCIAL ACTIVITIES
INCLUDING INCOME AND EXPENDITURE ACCOUNT
FOR THE YEAR ENDED 31 MARCH 2025

	Notes	Unrestricted funds 2025 £	Unrestricted funds 2024 £
Income from:			
Donations and legacies	3	123,185	121,963
Investments	4	5,363	4,864
Total income		128,548	126,827
Expenditure on:			
Raising funds	5	1,100	1,281
Charitable activities	6	131,783	138,011
Other expenditure	11	271	-
Total expenditure		133,154	139,292
Net expenditure and movement in funds		(4,606)	(12,465)
Reconciliation of funds:			
Fund balances at 1 April 2024		403,712	416,177
Fund balances at 31 March 2025		399,106	403,712

The statement of financial activities includes all gains and losses recognised in the year. All income and expenditure derive from continuing activities.

HISTIOCYTOSIS UK
HISTIO UK
BALANCE SHEET

AS AT 31 MARCH 2025

		2025		2024	
	Notes	£	£	£	£
Fixed assets					
Tangible assets	13		387		850
Current assets					
Debtors	14	981		941	
Cash at bank and in hand		403,027		405,383	
		404,008		406,324	
Creditors: amounts falling due within one year	15	(5,289)		(3,462)	
Net current assets			398,719		402,862
Total assets less current liabilities			399,106		403,712
Net assets			399,106		403,712
The funds of the charity					
Unrestricted funds			399,106		403,712
			399,106		403,712

The financial statements were approved by the trustees on 17.06.2025

Mr A Kontoyannis, Chair
Trustee

**HISTIOCYTOSIS UK
HISTIO UK
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2025**

1 Accounting policies

1.1 Accounting convention

The financial statements have been prepared in accordance with the charity's governing document, the Charities Act 2011 and "Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019)". The charity is a Public Benefit Entity as defined by FRS 102.

The charity has taken advantage of the provisions in the SORP for charities applying FRS 102 Update Bulletin 1 not to prepare a Statement of Cash Flows.

The financial statements have departed from the Charities (Accounts and Reports) Regulations 2008 only to the extent required to provide a true and fair view. This departure has involved following the Statement of Recommended Practice for charities applying FRS 102 rather than the version of the Statement of Recommended Practice which is referred to in the Regulations but which has since been withdrawn.

The financial statements are prepared in sterling, which is the functional currency of the charity. Monetary amounts in these financial statements are rounded to the nearest £.

The financial statements have been prepared under the historical cost convention, [modified to include the revaluation of freehold properties and to include investment properties and certain financial instruments at fair value]. The principal accounting policies adopted are set out below.

1.2 Going concern

At the time of approving the financial statements, the trustees have a reasonable expectation that the charity has adequate resources to continue in operational existence for the foreseeable future. Thus the trustees continue to adopt the going concern basis of accounting in preparing the financial statements.

1.3 Charitable funds

Unrestricted funds are available for use at the discretion of the trustees in furtherance of their charitable objectives.

Restricted funds are subject to specific conditions by donors or grantors as to how they may be used. The purposes and uses of the restricted funds are set out in the notes to the financial statements.

Endowment funds are subject to specific conditions by donors that the capital must be maintained by the charity.

1.4 Income

Income is recognised when the charity is legally entitled to it after any performance conditions have been met, the amounts can be measured reliably, and it is probable that income will be received.

Cash donations are recognised on receipt. Other donations are recognised once the charity has been notified of the donation, unless performance conditions require deferral of the amount. Income tax recoverable in relation to donations received under Gift Aid or deeds of covenant is recognised at the time of the donation.

HISTIOCYTOSIS UK
HISTIO UK
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 MARCH 2025

1 Accounting policies

(Continued)

Legacies are recognised on receipt or otherwise if the charity has been notified of an impending distribution, the amount is known, and receipt is expected. If the amount is not known, the legacy is treated as a contingent asset.

1.5 Expenditure

All expenditure is recognised once there is a legal or constructive obligation to that expenditure, it is probable settlement is required and the amount can be measured reliably. All costs are allocated to the applicable expenditure heading that aggregate similar costs to that category. Where costs cannot be directly attributed to particular headings they have been allocated on a basis consistent with the use of resources, with central staff costs allocated on the basis of time spent, and depreciation charges allocated on the portion of the asset's use. Other support costs are allocated based on the spread of staff costs.

Raising funds

These are costs incurred in attracting voluntary income, the management of investments and those incurred in trading activities that raise funds.

Charitable activities

Charitable expenditure comprises those costs incurred by the charity in the delivery of its activities and services for its beneficiaries. It includes both costs that can be allocated directly to such activities and those costs of an indirect nature necessary to support them.

1.6 Tangible fixed assets

Tangible fixed assets are initially measured at cost and subsequently measured at cost or valuation, net of depreciation and any impairment losses.

Depreciation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following bases:

Office equipment	33% reducing balance
------------------	----------------------

The gain or loss arising on the disposal of an asset is determined as the difference between the sale proceeds and the carrying value of the asset, and is recognised in the statement of financial activities.

1.7 Impairment of fixed assets

At each reporting end date, the charity reviews the carrying amounts of its tangible assets to determine whether there is any indication that those assets have suffered an impairment loss. If any such indication exists, the recoverable amount of the asset is estimated in order to determine the extent of the impairment loss (if any).

1.8 Cash and cash equivalents

Cash and cash equivalents include cash in hand, deposits held at call with banks, other short-term liquid investments with original maturities of three months or less, and bank overdrafts. Bank overdrafts are shown within borrowings in current liabilities.

HISTIOCYTOSIS UK
HISTIO UK
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 MARCH 2025

1 Accounting policies

(Continued)

1.9 Financial Instruments

The charity has elected to apply the provisions of Section 11 'Basic Financial Instruments' and Section 12 'Other Financial Instruments Issues' of FRS 102 to all of its financial instruments.

Financial Instruments are recognised in the charity's balance sheet when the charity becomes party to the contractual provisions of the instrument.

Financial assets and liabilities are offset, with the net amounts presented in the financial statements, when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously.

Basic financial assets

Basic financial assets, which include debtors and cash and bank balances, are initially measured at transaction price including transaction costs and are subsequently carried at amortised cost using the effective interest method unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of the future receipts discounted at a market rate of interest. Financial assets classified as receivable within one year are not amortised.

Basic financial liabilities

Basic financial liabilities, including creditors and bank loans are initially recognised at transaction price unless the arrangement constitutes a financing transaction, where the debt instrument is measured at the present value of the future payments discounted at a market rate of interest. Financial liabilities classified as payable within one year are not amortised.

Debt instruments are subsequently carried at amortised cost, using the effective interest rate method.

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of operations from suppliers. Amounts payable are classified as current liabilities if payment is due within one year or less. If not, they are presented as non-current liabilities. Trade creditors are recognised initially at transaction price and subsequently measured at amortised cost using the effective interest method.

Derecognition of financial liabilities

Financial liabilities are derecognised when the charity's contractual obligations expire or are discharged or cancelled.

1.10 Employee benefits

The cost of any unused holiday entitlement is recognised in the period in which the employee's services are received.

Termination benefits are recognised immediately as an expense when the charity is demonstrably committed to terminate the employment of an employee or to provide termination benefits.

HISTIOCYTOSIS UK
HISTIO UK
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 MARCH 2025

2 Critical accounting estimates and judgements

In the application of the charity's accounting policies, the trustees are required to make judgements, estimates and assumptions about the carrying amount of assets and liabilities that are not readily apparent from other sources. The estimates and associated assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates.

The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised where the revision affects only that period, or in the period of the revision and future periods where the revision affects both current and future periods.

3 Income from donations and legacies

	Unrestricted funds 2025 £	Unrestricted funds 2024 £
Donations and gifts	123,185	121,963
Donations and gifts		
Donations	122,926	120,569
Gift aid tax reclaimed	259	1,394
	123,185	121,963

4 Income from investments

	Unrestricted funds 2025 £	Unrestricted funds 2024 £
Interest receivable	5,363	4,864

HISTIOCYTOSIS UK
HISTIO UK
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 MARCH 2025

5 Raising funds

	Unrestricted funds	Unrestricted funds
	2025	2024
	£	£
General fundraising and event expenses	1,100	1,281
	<u>1,100</u>	<u>1,281</u>

6 Charitable activities

	Charitable Expenditure	Charitable Expenditure
	2025	2024
	£	£
Staff costs	58,986	58,986
Depreciation	191	419
Outreach costs	8,878	11,937
Travelling	4,056	4,289
Insurance	1,268	1,170
Telephone	1,334	4,077
Computer expenses	871	2,218
Printing, postage, stationery and advertising	2,142	3,103
Accountancy, bookkeeping and payroll fees	4,116	1,584
Bank charges	60	60
Interest payable	-	143
	<u>81,902</u>	<u>87,986</u>
Grant funding of activities (see note 7)	49,881	50,025
	<u>131,783</u>	<u>138,011</u>

HISTIOCYTOSIS UK
HISTIO UK
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 MARCH 2025

7 Grants payable

	Charitable Expenditure 2025 £	Charitable Expenditure 2024 £
Research costs	49,881	50,025
	49,881	50,025

8 Net movement in funds

	2025 £	2024 £
The net movement in funds is stated after charging/(crediting):		
Depreciation of owned tangible fixed assets	191	419
Loss on disposal of tangible fixed assets	271	-

9 Trustees

None of the trustees (or any persons connected with them) received any remuneration or benefits from the charity during the year.

10 Employees

The average monthly number of employees during the year was:

	2025 Number	2024 Number
	1	1
Employment costs	2025 £	2024 £
Wages and salaries	58,986	58,986

There were no employees whose annual remuneration was more than £60,000.

HISTIOCYTOSIS UK
HISTIO UK
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 MARCH 2025

11 Other expenditure

	Unrestricted funds 2025 £	Unrestricted funds 2024 £
Net loss on disposal of tangible fixed assets	271	-

12 Taxation

The charity is exempt from taxation on its activities because all its income is applied for charitable purposes.

13 Tangible fixed assets

	Office equipment £
Cost	
At 1 April 2024	
Disposals	5,490
	(3,568)
At 31 March 2025	1,922
Depreciation and impairment	
At 1 April 2024	
Depreciation charged in the year	4,640
Eliminated in respect of disposals	191
	(3,296)
At 31 March 2025	1,535
Carrying amount	
At 31 March 2025	387
At 31 March 2024	850

14 Debtors

	2025 £	2024 £
Amounts falling due within one year:		
Prepayments and accrued income	981	941

HISTIOCYTOSIS UK
HISTIO UK
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 MARCH 2025

15 Creditors: amounts falling due within one year

	2025	2024
	£	£
Other taxation and social security	2,655	1,950
Accruals and deferred income	2,634	1,512
	<u>5,289</u>	<u>3,462</u>

16 Analysis of net assets between funds

	Unrestricted funds 2025 £
At 31 March 2025:	
Tangible assets	387
Current assets/(liabilities)	398,719
	<u>399,106</u>
	Unrestricted funds 2024 £
At 31 March 2024:	
Tangible assets	850
Current assets/(liabilities)	402,862
	<u>403,712</u>

17 Related party transactions

There were no disclosable related party transactions during the year (2024 - none).

Document Activity Report

Document Sent

Wed, 23 Jul 2025 15:25:48 GMT

Document Activity History

Document history shows most recent activity first

Date

Activity

You can verify that this is a genuine Portal document by uploading it to the following secure web page:

<http://tcgroup2.accountantspace.co.uk/messages/VerifyDocument>